(Reuters) -Britain's GSK and partner Vir said on Friday their antibody-based COVID-19 drug was shown in a trial to work as well when given as a shot in the arm awhen administered via the standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback